Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi Takes On Drug Shortages With Iodixanol Launch

German Firm Has Also Launched First Generic Romidepsin Rival To Istodax

Executive Summary

Fresenius Kabi has launched a generic iodixanol injection in the US, at a time when the drug is subject to a nationwide shortage. At the same time, the firm has introduced the country’s first Istodax rival.

You may also be interested in...



Increased Transparency Key To Combating Drug Shortages, Says US Industry Alliance

The closure of a Teva manufacturing plant in California has raised concerns around access a number of medicines, something the End Drug Shortages Alliance says could be avoided through increased market transparency.

Fresenius Kabi Introduces Cancer Copay Scheme For Generics

German pharma giant Fresenius Kabi has introduced a copay scheme for a number of its generic oncology medicines in the US, which could completely eliminate monthly costs for certain patients.

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel